Allied Corp.

ALID

US0191141078

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:30:33 2024-04-26 pm EDT			5-day change	1st Jan Change
0.162 ^USD	+4.38%		-1.22%	+90.59%

Apr. 19	Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
Mar. 29	Allied Corp. Announces Resignation of Santiago Ribero as Director	CI

Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023

April 19, 2023 at 02:46 pm EDT

Allied Corp. reported earnings results for the second quarter and six months ended February 28, 2023. For the second quarter, the company reported net loss was USD 2.06 million compared to USD 2.33 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
For the six months, sales was USD 0.069625 million compared to USD 0.042556 million a year ago. Net loss was USD 3.37 million compared to USD 12.39 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.14 a year ago.

Latest news about Allied Corp.

Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 19	CI
Allied Corp. Announces Resignation of Santiago Ribero as Director	Mar. 29	CI
Allied Corp. Moves Its Headquarters	Mar. 29	CI
Allied Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 16	CI
Allied Corp. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 14	CI
Allied Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-08-10	CI
Allied Corp. announced a financing transaction	23-07-05	CI
Allied Corp. Signs Joint Venture with Blueberries Medical Corp. to Expand Product Offering and Bring Derivative Products to Global Markets	23-04-26	CI
Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-19	CI
Allied Corp. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-22	CI
Allied Corp. Reports Earnings Results for the Full Year Ended August 31, 2022	22-12-14	CI
Allied Corp. Auditor Raises 'Going Concern' Doubt	22-12-13	CI
Allied Corp. Successfully Executes on Another Sale & Export of Colombian Produced Cannabis Flower	22-12-05	CI
Allied Corp. announced that it has received $1.47 million in funding	22-10-30	CI
Allied Corp Receives The Brazilian Health Regulatory Agency Approval for Brazilian Import	22-08-23	CI
Allied Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-20	CI
Allied Corp. Successfully Ships Second Commercial Cannabis Flower Export from Colombia to International Market	22-07-14	CI
Allied Corp Successfully Ships First Commercial Cannabis Flower Export from Colombia to International Market	22-06-29	CI
Allied Corp. Announces the Approval of Its 2022 Quota for the Production and Sale of THC Cannabis Flower	22-05-03	CI
Allied Corp. Announces Initial USD 147,000 Purchase Order Continuing into Monthly Supply Agreement for Brazilian Specialty Cancer Care Hospital	22-04-27	CI
Allied Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	22-04-18	CI
Allied Corp Commends Colombian Government for Announcing the Final Approval of the Regulations for the Export of Cannabis from Colombia	22-04-04	CI
Allied Corp Completes Another Sales Transaction with Re-Order from Customer	22-03-11	CI
Allied Corp Signs Sales Order for 1,000Kgs Worth €1 Million of Cannabis Flower	22-02-07	CI
Allied Corp. Reports Earnings Results for the First Quarter Ended November 30, 2021	22-01-19	CI

Chart Allied Corp.

Duration

Period

More charts

Company Profile

Allied Corp. is an international medical cannabis production company. The Company is focused on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment there with. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinsonâs disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1. Its wholly owned subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ALLIED CORP.	+90.59%	17.14M
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B